qualitative and quantitative composition

each tablet contains 200mg cefixime (anhydrous).

it is an orally active cephalosporin antibiotic which has marked in vitro bactericidal activity against a wide variety of gram-positive and gram-negative organisms.

it is indicated for the treatment of the following acute infections when caused by susceptible micro-organisms:

upper respiratory tract infections (urti): e.g. Otitis media; and other urti where the causative organism is known or suspected to be resistant to other commonly used antibiotics, or where treatment failure may carry significant risk.

lower respiratory tract infection: e.g. Bronchitis.

urinary tract infections: e.g. Cystitis, cystourethritis, uncomplicated pyelonephritis.

clinical efficacy has been demonstrated in infections caused by commonly occuring pathogens including streptococcus pneumoniae, streptococcus pyogenes, escherichia coli, proteus mirabilis, kliebsiella species, haemophilus influenzae (beta-lactamase positive and negative), branhamella catarrhalis (beta- lactamase positive and negative) and enterobacter species. Suprax is highly stable in the presence of beta-lactamase enzymes.

most strains of enterococci (streptococcus faecalis, group d streptococci) and staphylococci (including coagulase positive and negative strains and meticillin- resistant strains) are resistant to suprax. In addition, most strains of pseudomonas, bacteriodes fragalis, listeria monocytogenes and clostridia are resistant to suprax.

qualitative and quantitative composition

each tablet contains 200mg cefixime (anhydrous).

it is an orally active cephalosporin antibiotic which has marked in vitro bactericidal activity against a wide variety of gram-positive and gram-negative organisms.

it is indicated for the treatment of the following acute infections when caused by susceptible micro-organisms:

upper respiratory tract infections (urti): e.g. Otitis media; and other urti where the causative organism is known or suspected to be resistant to other commonly used antibiotics, or where treatment failure may carry significant risk.

lower respiratory tract infection: e.g. Bronchitis.

urinary tract infections: e.g. Cystitis, cystourethritis, uncomplicated pyelonephritis.

clinical efficacy has been demonstrated in infections caused by commonly occuring pathogens including streptococcus pneumoniae, streptococcus pyogenes, escherichia coli, proteus mirabilis, kliebsiella species, haemophilus influenzae (beta-lactamase positive and negative), branhamella catarrhalis (beta- lactamase positive and negative) and enterobacter species. Suprax is highly stable in the presence of beta-lactamase enzymes.

most strains of enterococci (streptococcus faecalis, group d streptococci) and staphylococci (including coagulase positive and negative strains and meticillin- resistant strains) are resistant to suprax. In addition, most strains of pseudomonas, bacteriodes fragalis, listeria monocytogenes and clostridia are resistant to suprax.